

Press Release

NeuroVive Pharmaceutical AB (publ), 556595-6538
28 April 2020 08:30:00 CEST - Lund, Sweden



NeuroVive's Nomination Committee amends its proposal to the 2020 Annual General Meeting

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) today announced that the Company's Nomination Committee in its proposal to the Annual General Meeting May 20, 2020, added a proposal regarding an additional Board member.

The Nomination Committee's amended proposal follows the news announced in a press release April 22, 2020, regarding a directed issue to Hadean Ventures and the condition to elect Dr Roger Franklin as Director of NeuroVive's Board of Directors at a General Meeting on or prior to June 15, 2020.

In the Nomination Committee's proposal, which was published on April 20, 2020, the Nomination Committee submitted the following proposals to the Annual General Meeting: Chairman of the Annual General Meeting, election of the Chairman of the Board and other members of the Board, Board fees to the Chairman of the Board and members of the Board, remuneration for any committee work and election of auditors and fees, and guidelines for appointing members of the Nomination Committee and instructions for the Nomination Committee.

The Nomination Committee thus proposes the following:

Determination of the number of Board members and auditors, and determination of Directors' and audit fees (point 11 and 12)

The Nomination Committee proposes that the Annual General Meeting resolves that the number of Board members shall be six and that one auditor shall be appointed. The Nomination Committee also proposes that fees to Board members elected by the Annual General Meeting not employed by the Company and members of the Board of Directors' various Committees not employed by the Company shall be payable, as in the previous year, as follows:

- SEK 400,000 to the Chair of the Board;
- SEK 250,000 each to other Board members;
- SEK 100,000 to the Chair of the Audit Committee;
- SEK 50,000 each to other members of the Audit Committee;
- SEK 40,000 to the Chair of the Remuneration Committee;
- SEK 20,000 each to other members of the Remuneration Committee.

Having considered the Company's and the Board of Directors' appraisal of the auditors' work, the Nomination Committee proposes that as in the previous year, audit fees should be in accordance with approved account pursuant to customary billing terms. No fees shall be payable to members of the Nomination Committee.

Election of the Board of Directors and auditor (point 13)

The Nomination Committee proposes that the Annual General Meeting approves re-election of the following Board members: David Bejker, Denise Goode, David Laskow-Pooley, Magnus Persson and Jan Törnell. The Nomination Committee also proposes the election of Roger Franklin as Board member. The Nomination Committee proposes that David Laskow-Pooley is re-elected as Chair of the Board.

Press Release

NeuroVive Pharmaceutical AB (publ), 556595-6538
28 April 2020 08:30:00 CEST - Lund, Sweden



Currently Stockholm-based partner at Hadean Ventures, Roger Franklin (born 1979), PhD, has wide ranging experience in life science and innovation spanning over a decade across the venture capital, investment banking and consulting industries. Prior to his business career, Roger completed his academic training in biochemistry at Oxford University before specializing in oncology during his doctoral work at Cambridge's Laboratory of Molecular Biology (LMB). Before joining Hadean Ventures, Roger was senior pharmaceutical and biotechnology analyst at Liberum, a London based investment bank. Roger holds no shares in NeuroVive and is non-affiliated to the Company, the management and to major owners.

Furthermore, the Nomination Committee proposes that auditor firm MAZARS SET Revisionsbyrå AB are re-elected as the Company's auditor, for the period until the end of the Annual General Meeting held in the financial year after the Auditor was appointed.

The Nomination Committee for the 2020 AGM comprises: Kristina Ingvar, Chair, for John Fällström, Andreas Inghammar for Rothesay Ltd and Michael Vickers for Maas Biolab LLC.

The Nomination Committee's other proposals to the Annual General Meeting remain unchanged.

For more information, please contact:

Catharina Johansson, CFO, IR & Communications
+46 (0)46-275 62 21, ir@neurovive.com

NeuroVive Pharmaceutical AB (publ)

Medicon Village, SE-223 81 Lund, Sweden

Tel: +46 (0)46 275 62 20 (switchboard)

info@neurovive.com, www.neurovive.com

For news subscription, please visit <http://www.neurovive.com/press-releases/subscription-page/>

Follow us on [LinkedIn](#)

Subscribe to our [YouTube channel](#)

About Us

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase I (KL1333) for chronic treatment of primary mitochondrial diseases and one project, in preparation for clinical trials (NV354), for treatment of primary mitochondrial diseases with Complex I deficiency. NeuroSTAT for traumatic brain injury (TBI) is ready to enter a clinical phase II efficacy study. The R&D portfolio also consists of early projects. NeuroVive's ambition is to take drugs for primary mitochondrial diseases through clinical development and all the way to market, with or without partners. For the TBI and NASH projects the goal is to enter strategic partnerships. A subset of compounds under NeuroVive's NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber's Hereditary Optic Neuropathy (LHON). NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTC Market's Pink Open market in the US (OTC: NEVPF).

Attachments

NeuroVive Pharmaceutical AB (publ) - the mitochondrial medicine company. The company is listed on Nasdaq Stockholm, Small Cap, under the ticker symbol NVP. The share is also traded on the OTC Markets' Pink Open market (ticker symbol NEVPF) in the US. Investors can find Real-Time quotes and market information for the company at www.otcm Markets.com/stock/NEVPF/quote.

Press Release

NeuroVive Pharmaceutical AB (publ), 556595-6538
28 April 2020 08:30:00 CEST - Lund, Sweden



[NeuroVive's Nomination Committee amends its proposal to the 2020 Annual General Meeting](#)